Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21294545 | 0.96 | ACSS2 (0.55) | ACSS2LMNAHTTPKMMAPT | |
| SCHEMBL21294443 | 0.89 | ACSS2 (0.63) | ACSS2LMNAHTTPKMMAPT | |
| SCHEMBL29433493 | 0.85 | HTT (0.53) | ACSS2LMNAHTTPKMMAPT | |
| SCHEMBL21294539 | 0.85 | ACSS2 (0.71) | ACSS2LMNAHTTPKMMAPT | |
| SCHEMBL29433574 | 0.85 | ACSS2 (0.75) | ACSS2LMNAHTTPKMMAPT | |
| SCHEMBL21305585 | 0.85 | ACSS2 (0.75) | ACSS2LMNAHTTPKMMAPT | |
| SCHEMBL29433482 | 0.82 | ACSS2 (0.73) | ACSS2LMNAHTTPKMKDM4E | |
| SCHEMBL21294409 | 0.82 | ACSS2 (0.73) | ACSS2LMNAHTTPKMKDM4E | |
| SCHEMBL22670090 | 0.82 | LMNA (0.49) | ACSS2LMNAHTTPKMMAPT | |
| SCHEMBL11483889 | 0.82 | MAPT (0.66) | ACSS2LMNAHTTPKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| CN-111566092-B | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| EP-3710430-B9 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2024-10-30 | — | — | EP | disclosed |
| EP-3710430-B1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2024-07-03 | — | — | EP | disclosed |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| CN-114008025-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | METABOMED LTD. (IL) | 2020-12-01 | — | — | US | disclosed |
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | METABOMED LTD. (IL) | 2020-12-01 | — | — | US | disclosed |
| WO-2020230136-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2019-08-29 | — | — | US | disclosed |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | ACSS2 1/4885LMNA 3876/4885HTT 4784/4885 |
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | ACSS2 1/4885LMNA 3876/4885HTT 4784/4885 |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | ACSS2 1/4885LMNA 3876/4885HTT 4784/4885 |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | ACSS2 1/4885LMNA 3876/4885HTT 4784/4885 |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | ACSS2 1/4885LMNA 3876/4885HTT 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.